Effective Antiviral Therapy Improves Immunosuppressive Activities in the Immune Microenvironment of Hepatocellular Carcinoma by Alleviating Inflammation and Fibrosis
Cancer Medicine · 2024
DOI: 10.1002/cam4.70459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Zhu-Tao Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Tumor Microenvironment, Antiviral Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, foundation of Zhongshan Hospital.
Abstract (Originalsprache)
Background and Aims The immune microenvironment (IME) plays a crucial role in the progression of hepatocellular carcinoma (HCC). In HCC, the IME is often compromised by hepatitis B virus (HBV) infection, chronic inflammation, and fibrosis. Both antiviral therapy (AVT) and the alleviation of inflammation and fibrosis (AIF) have been shown to improve prognosis. However, the relationship among the IME of HCC, AVT, and AIF remains unclear.
Methods
A total of 140 and 110 primary HBV‐related HCC patients were enrolled as training and validation sets, respectively, to establish a HCC‐immune microenvironment score (H‐IME score). Immunohistochemistry was performed to assess the number of granzyme B+ (GrB+) and Foxp3+ cells, as well as the expression of CTLA‐4, PD‐1, LAG3, TIGIT, TIM3, and VISTA. Another cohort consisting of 114 recurrent HBV‐related HCC patients with paired primary and recurrent tissues was used to study the relationship among the IME of HCC, AVT, and AIF.
Results
The H‐IME score, including GrB, Foxp3, CTLA‐4, PD‐1, LAG3, and TIGIT, was established to evaluate the IME. A higher H‐IME score indicates stronger immunosuppressive activities. Both AVT and AIF were found to inhibit immunosuppressive activities in the IME. Compared to primary tumors, the H‐IME scores of recurrent tumors in the effective AVT group (e‐AVT, classified by HBV DNA) with AIF decreased, while the scores increased in the non‐AVT group without AIF.
Conclusions
The IME of HCC is closely related to AVT and AIF. e‐AVT can enhance anti‐tumor activities in the IME by alleviating inflammation and fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China.
- Liver Cancer Institute and Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Zhu-Tao Wang, Jian Zhou, Jia Fan
Förderung
- National Natural Science Foundation of China
- foundation of Zhongshan Hospital
Zitieren
APA
Wang, Z. T., Guan, R. Y., Gan, W., Yang, Z. F., Sun, B. Y., Wu, J. F., Zhang, D., Sun, G. Q., Gao, X. K., Huang, J. L., Liu, G., Zhou, C., Zhou, J., Fan, J., Yi, Y., Hu, B., & Qiu, S. J. (2024). Effective Antiviral Therapy Improves Immunosuppressive Activities in the Immune Microenvironment of Hepatocellular Carcinoma by Alleviating Inflammation and Fibrosis. Cancer Medicine. https://doi.org/10.1002/cam4.70459
Vancouver
Wang ZT, Guan RY, Gan W, Yang ZF, Sun BY, Wu JF, et al. Effective Antiviral Therapy Improves Immunosuppressive Activities in the Immune Microenvironment of Hepatocellular Carcinoma by Alleviating Inflammation and Fibrosis. Cancer Medicine. 2024. doi:10.1002/cam4.70459
BibTeX
@article{Wang2024,
author = {Wang, Zhu-Tao and Guan, Ruo-Yu and Gan, Wei and Yang, Zhang-Fu and Sun, Bao-Ye and Wu, Jing-Fang and Zhang, Dai and Sun, Guo-Qiang and Gao, Xu-Kang and Huang, Jin-Long and Liu, Gao and Zhou, Cheng and Zhou, Jian and Fan, Jia and Yi, Yong and Hu, Bo and Qiu, Shuang-Jian},
title = {Effective Antiviral Therapy Improves Immunosuppressive Activities in the Immune Microenvironment of Hepatocellular Carcinoma by Alleviating Inflammation and Fibrosis},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70459}
}
EUVIMED